-

$undefined

N/A

(N/A)

Adlai Nortye Biopharma :ANL

Location: | Industry: | Sector:

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

190.2M

Cash

61.16M

Avg Qtr Burn

-12.95M

Short % of Float

0.01%

Insider Ownership

5.66%

Institutional Own.

0.18%

Qtr Updated

12/31/24

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Buparlisib/AN2025 + Paclitaxel Details Cancer, Head and neck squamous cell carcinoma	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Buparlisib/AN2025 in comb w/chemoradiotherapy and radiotherapy Details Cancer, Rectal cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AN0025 + definitive chemoradiotherapy (dCRT) Details Cancer, Esophageal cancer	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.